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Abstract
Background: Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is characterized by recurrent attacks
of swelling that affect various body sites. Such attacks are a frequent cause of visits to the emergency department
and are often treated in the hospital. In recent years, self-administration of C1-inhibitor (C1-INH) concentrates at
home has become an increasingly used option, with a positive impact on patient outcomes and quality of life.
Methods: This was an observational study of 6 months’ duration in 56 patients with C1-INH-HAE referred to a HAE
center in southern Italy. The patients received three types of treatment for their swelling attacks: C1-INH
concentrates administered at home (n = 25); icatibant administered at home (n = 12); and C1-INH concentrates
administered in the hospital (n = 19). The objectives of this observational study were to compare therapy
compliance (defined as the proportion of treated attacks) and quality of life in home- and hospital-treated patients,
and to identify factors associated with the decision to use home therapy.
Results: Overall, 918 attacks were reported over 6 months, of which 544 (59.2 %) were treated. Total number of reported
attacks and the mean (±SD) number of attacks per patient, respectively, in the three groups were: 611 and 24.4 (±26.1) for
home-based C1-INH; 191 and 15.9 (±12.0) for home-based icatibant; 166 and 6.1 (±6.5) for hospital-based C1-INH.
Differences in attack frequency between home- and hospital-based treatments were statistically significant (p = 0.002),
while patient demographic characteristics and the disease severity score did not correlate with the use of home therapy.
Compliance with therapy was significantly better with home-based therapy (71.2 % of treated attacks with C1-INH and 44.
0 % with icatibant) than with hospital-based therapy (21.6 %, p = 0.003). Quality of life showed an opposite trend, with
patients on hospital-based treatment reporting the highest quality of life.
Conclusions: Home-based therapy was associated with better compliance compared with hospital-based therapy. The
choice to adopt home-based therapy appeared to correlate with a high attack frequency. Home-based therapy is a valid
treatment option for patients with C1-INH-HAE and should be offered to all such patients, and especially to those with
high attack frequency.
Keywords: C1-inhibitor deficiency, Hereditary angioedema, C1-inhibitor concentrates, Icatibant, Home therapy, Self-
administration, Attack frequency
* Correspondence: bovamaria@virgilio.it; marone@unina.it
1Dipartimento di Science Mediche Traslazionali, Università degli Studi di
Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Squeglia et al. Orphanet Journal of Rare Diseases  (2016) 11:133 
DOI 10.1186/s13023-016-0518-8
Background
Hereditary angioedema with C1-inhibitor deficiency (C1-
INH-HAE) is a rare disease marked by recurrent attacks
of swelling that affect various body sites including the
gastrointestinal tract, the extremities, the face, the larynx,
and the urogenital region [1, 2]. Deficiency in C1-esterase
inhibitor (C1-INH) results in the overproduction of brady-
kinin and activation of bradykinin B2 receptors leading to
increased vascular permeability and edema [3].
Severity and frequency of the attacks and the body site
affected are unpredictable. HAE attacks can be associ-
ated with severe pain and can be life-threatening when
the upper airways are involved, due to the risk of as-
phyxiation. They are a frequent cause of visits to the
emergency department and, until recently, HAE treat-
ment was predominantly hospital-based [4, 5]. In recent
years, home-based therapy, involving self-administration
of therapy or administration by a family member, has
been increasingly offered to HAE patients [6]. The evi-
dence suggests that this treatment option may reduce
the burden of HAE and improve patient quality of life
(QoL) [7, 8]. Home administration of on-demand treat-
ment usually results in a shorter time from the onset of
attack to the initiation of treatment, shorter attack dur-
ation, and less severe attacks [9–14]. In addition, several
studies have shown that home administration of HAE
therapies is safe, with a low incidence of adverse events
[10, 12, 15, 16]. According to current international
guidelines for the treatment of HAE, home-based ther-
apy should be the preferred strategy whenever possible
[17–20]. Treatments licensed in Europe for self-
administration include plasma-derived (pd) C1-INH
concentrates (Berinert®, Cinryze®) and icatibant (Firazyr®),
a bradykinin B2 receptor antagonist.
We recently published the results from our experience
in teaching pdC1-INH self-administration to a group of
patients with C1-INH-HAE [21]. The self-injection
training course was proposed to all patients referred to
our center; about 40 % attended. Approximately half of
the patients who attended the training course decided to
switch to home-based therapy. To improve the rate of
patients practicing self-therapy and to optimize the se-
lection of patients best suited for this treatment option,
we set out to investigate what might affect patients’
choices. We report here the results of an observational
study involving all the patients referring to our center
and receiving three different types of treatment for their
acute attacks, namely home-based pdC1-INH, self-
injection of icatibant, or hospital-based pdC1-INH. This
study aimed to compare demographic and clinical char-
acteristics, adherence to treatment, and quality of life in
patients treated at home versus (vs.) patients treated in
the hospital, with the ultimate goal of identifying factors
predictive of the choice to initiate home-based therapy.
Methods
Study design and patients
This was an observational study of 6 months’ duration,
and included all patients with a diagnosis of C1-INH-
HAE (type I and type II) in treatment at an HAE referral
center in southern Italy, between August 2014 and Janu-
ary 2015. The patients were divided into three groups
according to the type of treatment they were receiving
for their acute attacks, namely: home-based therapy with
C1-INH concentrate (Berinert®, CSL Behring; or Cin-
ryze®, Shire; administered by intravenous infusion);
home-based therapy with icatibant (Firazyr®, Shire; ad-
ministered by subcutaneous injection); hospital-based
therapy with C1-INH concentrate (Berinert®). In all
groups, treatments were administered according to the
manufacturer’s indications and local guidelines. The ob-
jectives of the study were: 1) to compare compliance
with therapy and quality of life in patients treated at
home vs. hospital at the end of the 6 month-observation
period and; 2) to identify factors associated with the de-
cision to adopt home therapy. The study was approved
by the local institutional review board (Comitato Etico
Università “Federico II”, Naples, Italy). All patients, or
parents/legal guardians for minors, gave their informed
consent to data collection and analysis.
Self-administration training
Icatibant is administered subcutaneously and patients
are taught self-administration during regular visits to
their physician, at the first prescription of this medica-
tion [22]. pdC1-INH concentrates are administered by
intravenous infusion and patients require more extensive
training before feeling comfortable with this administra-
tion route. As previously described, in 2010, our center
initiated a training program to instruct patients on self-
administration of pdC1-INH concentrates by intraven-
ous infusion [21]. The training course consisted of a the-
ory session and a practical session during which
participants could practice intravenous injection on a
simulator arm. Participants were also instructed on how
to behave in case of a laryngeal attack, or if unable to
administer treatment, and were invited to keep a diary
documenting attack characteristics, treatment adminis-
tered, time from symptom onset to treatment adminis-
tration, time from treatment administration to symptom
resolution, and other relevant features of home therapy.
Assessments
Patients were visited at baseline (beginning of observa-
tion) and followed up for 6 months, and were inter-
viewed once monthly during a phone call conducted by
trained personnel. At baseline, demographic data were
collected and recorded in a patient chart designed for
the study. Other data recorded in the patient chart were
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the number of attacks in the previous month, the num-
ber of treated attacks, the time from symptom onset to
treatment administration, and the time from treatment
administration to symptom resolution for each attack.
These data were extracted from patients’ diaries. Disease
severity was also established. To this purpose we used
the general disease severity score developed by Bygum
and coworkers [23]. This score ranges from 0 to 10 (10
corresponds to the highest disease severity) and is based
on the age at disease onset, number of organs ever af-
fected, and need for long-term prophylaxis (age at onset
0–5 years, 3 points; age at onset 6–10 years, 2 points;
age at onset, 11–20 years, 1 point; age at onset > 20 years,
0 points; skin edema ever, 1 point; painful abdominal
edema ever, 2 points; laryngeal edema ever, 2 points;
other clinical manifestations, 1 point; long-term prophy-
laxis ever, 1 point). In contrast with other disease sever-
ity assessment tools, this score does not consider a
specific time frame, and is based on medical records and
a patient interview thereby reducing recall bias and sub-
jective interpretation. Compliance with therapy was de-
fined as the proportion of attacks that were treated over
the entire observation period. Quality of life was
assessed in adults, at the end of the observation, using
the disease-specific HAE-QoL questionnaire designed by
Prior and colleagues [24]. The questionnaire considers
seven domains relevant for quality of life: physical func-
tioning and health (four questions, score range 4–23);
disease-related stigma (three questions, score range 3–
15); emotional role and social functioning (four ques-
tions, score range 4–20); concern about offspring (two
questions, score range 2–10); perceived control over ill-
ness (four questions, score range 4–20); mental health
(four questions, score range 4–24); treatment difficulties
(four questions, score range 4–23). The maximum score
is 135, and higher scores indicate better quality of life.
The HAE-QoL questionnaire, which is validated for use
in subjects aged ≥ 18 years, is protected by Spanish intel-
lectual property law and owned by La Fundación para la
Investigación Biomédica del Hospital Universitario La
Paz (Madrid, Spain). It was kindly made available to us
by T. Caballero (Hospital La Paz Institute for Health Re-
search, Madrid, Spain).
Data analysis
Data were analyzed by descriptive statistics. Means and
standard deviations of measured variables and propor-
tions of treated attacks were calculated. A correlation
analysis using the Pearson χ2 test, with p ≤ 0.05 defining
statistical significance, was performed to establish
whether the choice of treatment strategy (home-based
or hospital-based) might correlate with factors including
age (pediatric age [<15 years] and adult age [≥15 years]),
age at diagnosis, sex, level of education, disease severity
score, and total number of attacks over the observation
period. The correlation between disease severity score
(≥7 [severe disease] or < 7 [mild to moderate disease])
and choice of therapeutic strategy, compliance, and qual-
ity of life was also investigated. Statistical analysis was
performed using IBM SPSS Statistics software.
Results
Between August 2014 and January 2015, a total of 62 pa-
tients affected by C1-INH-HAE were in treatment at our
center. Six patients were lost to follow-up. The
remaining 56 (60.7 % female, mean [±SD] age 36 years
[±19.6]) were divided into three groups according to
treatment received: home-based therapy with pdC1-INH
(n = 25), home-based therapy with icatibant (n = 12), and
hospital-based therapy with pdC1-INH (n = 19). Charac-
teristics of the study population and treatment groups
are summarized in Table 1. Twelve of the 56 patients
observed (21.4 %) were aged < 15 years. The mean dis-
ease severity score determined according to Bygum et al.
[23] was 6.9 (maximum severity score = 10) in the over-
all population and 7.3, 6.7, and 6.6 in patients receiving
home-based pdC1-INH, home-based icatibant, and
hospital-based pdC1-INH, respectively; 60.0 %, 58.3 %,
and 47.4 % of patients in the three treatment groups, re-
spectively, had severe disease (score ≥ 7). No statistically
significant differences were found in the mean disease
severity score and in the proportion of patients with se-
verity score ≥ 7 between home-based and hospital-based
therapy and between treatment strategies.
On average, patients had been on home-based therapy
for 25 months with pdC1-INH concentrates and for
33 months with icatibant. Thirteen patients (23.2 %)
were using long-term prophylaxis with danazol (n = 9),
stanazolol (n = 1), or C1-INH concentrates (n = 3).
During the 6-month observation period, a total of 918
attacks were reported, of which 544 (59.2 %) were
treated. Patients treated with pdC1-INH home-based
therapy had a total of 611 attacks (mean [±SD] per pa-
tient attack number, 24.4 [±26.1] over 6 months), and
those treated with icatibant home-based therapy had a
total of 191 attacks (mean [±SD] per patient attack num-
ber, 15.9 [±12.0] over 6 months): Fig. 1a. Patients receiv-
ing hospital-based pdC1-INH therapy had a total of 116
(mean [±SD] per patient attack number, 6.1 [±6.5] over
6 months). The difference in the total number of attacks
between home-based therapy (with pdC1-INH and icati-
bant) and hospital-based therapy was statistically signifi-
cant (p = 0.002, Pearson χ2 test).
Patients on home-based therapy had better compliance
as suggested by the greater proportion of treated attacks
(435/611 [71.2 %] with pdC1-INH and 84/191 [44.0 %]
with icatibant), relative to those receiving hospital-based
pdC1-INH treatments (25/116 [21.6 %]): Fig. 1b. The
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difference in the rates of treated attacks between home-
based therapy (with pdC1-INH and icatibant) and
hospital-based therapy was statistically significant (p =
0.003, Pearson χ2 test).
The mean times from symptom onset to treatment ad-
ministration were similar among treatment groups (1.8
[±0.4], 2.6 [±1.1], and 3.1 [±9.7] hours respectively for
home-based pdC1-INH, home-based icatibant, and
hospital-based pdC1-INH), as were the mean times from
treatment administration to symptom resolution (11.3
[±10.2], 10.9 [±9.1], 13.2 [±12.3] hours, respectively). No
statistically significant differences were found in the
mean times from symptom onset to treatment adminis-
tration and from treatment administration to symptom
resolution between treatment groups.
The assessment of quality of life in adults using the
HAE-QoL [24] administered at the end of observation
showed that those with the best quality of life (highest
score) were the patients receiving hospital-based pdC1-
INH therapy (mean total score 116.7, 75th percentile of
healthy age- and sex-matched population), followed by
patients receiving home-based therapy with icatibant
(102.6, 56th percentile) and pdC1-INH home-based
therapy (99.5, 55th percentile): Fig. 2. The difference be-
tween treatment groups did not reach statistical
significance.
No statistically significant differences were seen be-
tween patients receiving home-based therapy or
hospital-based therapy, with regard to age (pediatric or
adult), age at diagnosis, sex, level of education, and dis-
ease severity score (Table 1). The disease severity score
was found to correlate significantly (p = 0.008) with qual-
ity of life, with more patients affected by severe disease
(32.2 %) having a worse quality of life (<50th percentile)
compared to those with mild to moderate disease
(16.7 %) (Table 2). No statistically significant correlation
was found between disease severity and treatment strat-
egy (p = 0.74) and between disease severity and compli-
ance (p = 0.32).
Discussion
This observational study involving 56 patients with C1-
INH-HAE who experienced over 900 swelling attacks
shows that home-based treatment (with pdC1-INH con-
centrates or icatibant) was associated with significantly
better therapy compliance, compared with hospital-
based treatment (with pdC1-INH concentrates). Patients
on home-based therapy with pdC1-INH and icatibant
treated over 70 % and 40 % of their attacks, respectively,
while patients receiving hospital-based care had only
about 20 % of their attacks treated. Quite unexpectedly,
quality of life showed a tendency to be better in patients
receiving hospital-based therapy. Patients on home-
based therapy were found to have a significantly greater
number of attacks (approximately 4 attacks/month in
patients using pdC1-INH and 3 attacks/month in those
using icatibant) compared with patients treated in the
hospital (approximately 1 attack/month), while no differ-
ences were found between patients on home- or
hospital-based therapy with regard to sex, age, age at
diagnosis, level of education, and disease severity.
The benefits of self-therapy for patients affected by
C1-INH-HAE are supported by a large body of evidence
[7, 8]. This is reflected in current guidelines for the man-
agement of C1-INH-HAE, according to which therapy
self-administration should be offered to all patients af-
fected by this condition [17–20]. Recent surveys, and
our experience as well, have shown that most patients
are willing to learn self-administration, and that self-
injection skills are acquired quite rapidly, with only a










Female 14 (56.0) 8 (66.7) 12 (63.2) 34 (60.7)
Male 11 (44.0) 4 (33.3) 7 (36.8) 22 (39.3)
Age, yrs, mean, (±SD) 33.0 (19.0) 36.0 (11.5) 39.5 (24.2) 36 (19.6)
Age
≥ 15 years, n (%) 18 (72.0) 12 (100.0) 14 (73.7) 44 (78.6)
< 15 years, n (%) 7 (28.0) 0 5 (26.3) 12 (21.4)
Age at diagnosis, yrs, mean, (±SD) 20 (16.0) 30 (12.0) 26 (20.0) 25 (17.0)
Time since diagnosis, yrs, mean, (±SD) 13.0 (8.0) 6.0 (6.0) 13.0 (12.0) 11 (9.0)
Disease severity score, mean, (range) 7.3 (3–10) 6.7 (4–9) 6.6 (3–10) 6.9 (3–10)
Duration of home therapy, months, mean, (range) 25.1 (6–60) 32.7 (12–60) - -
Receiving long-term prophylaxis, n (%) 6 (24.0) 2 (16.7) 5 (26.3) 13 (23.2)
Abbreviation definitions: pdC1-INH plasma-derived C1-esterase inhibitor concentrate, SD standard deviation
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minority of patients deciding against home therapy after
being trained [21, 25–29]. A recent paper discussing
strategies to facilitate home-based treatment, has under-
lined the importance of patient and disease characteris-
tics when evaluating the suitability of patients for
training in home therapy [8]. In particular, relevant pa-
tient and disease characteristics included mental and
physical ability to learn self-injection, patient reliability,
patient willingness and motivation, and presence of ad-
equate veins for intravenous administration. Among dis-
ease characteristics, high frequency of attacks made
home therapy very appropriate. As a rough guideline,
the authors suggested that patients who have at least
two attacks per month will get the greatest benefit, al-
though highly motivated patients with less frequent at-
tacks may also benefit from home therapy [8]. Patients
with a high frequency of attacks are also eligible for
long-term prophylaxis with C1-INH concentrates or at-
tenuated androgens, according to current guidelines
[18]. The decision to initiate prophylaxis depends how-
ever on several other factors, including disease severity,
patient quality of life, resource availability, and inad-
equate symptom control with on-demand therapy [18].
It should also be reminded that breakthrough attacks
occur in the majority of patients on prophylaxis, and
that on-demand therapy should remain available for
these patients [18]. Among our patients, less than one-
fourth were on prophylaxis, despite a mean disease se-
verity score close to 7 and indicative of a severe condi-
tion. According to our experience, treatments currently
available for C1-INH-HAE prophylaxis are refused by
some patients because of the inconvenient twice weekly
injection schedule (C1-INH-concentrate, Cynrize®), and
unfavorable side effect profile (attenuated androgens).
In the management of C1-INH-HAE, similarly to a
number of other chronic conditions, poor compliance is
a major, but often unrecognized problem leading to
therapeutic failure, adverse events, and avoidable med-
ical costs [30]. In patients treated at home, adherence to
therapy is even more crucial because such patients are
not regularly seen by a healthcare professional [28]. Ac-
cording to the results of a recent survey, therapy self-
administration is associated with high satisfaction with
treatment and good compliance with it [29]. Our find-
ings show a significantly better compliance (higher rate
of treated attacks) with treatment in the group receiving
a
b
Fig. 1 Attack frequency and compliance with treatment in the three
treatment groups over 6 months. Legend Mean number of attacks per
patient (a), proportion of attacks treated (compliance) (b); pdC1-INH=
plasma-derived C1-esterase inhibitor concentrate
Fig. 2 Mean scores for the 7 domains of the hereditary angioedema-
quality of life (HAE-QoL) assessment [24], by treatment group. Legend (1)
Physical functioning and health (4 questions, score range 4–23), (2)
Disease-related stigma (3 questions, score range 3–15), (3) Emotional role
and social functioning (4 questions, score range 4–20), (4) Concern about
offspring (2 questions, score range 2–10), (5) Perceived control over
illness (4 questions, score range 4–20), (6) Mental health (4 questions,
score range 4–24), (7) Treatment difficulties (4 questions, score range
4–23); pdC1-INH= plasma-derived C1-esterase inhibitor concentrate
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home-based therapy, relative to hospital-based therapy.
The lower rate of treated attacks in patients referring to
a hospital could be explained by the fact that the aware-
ness of rare diseases like C1-INH-HAE among the emer-
gency department personnel is often insufficient
resulting in the inadequate treatment of a swelling at-
tack, or no treatment [4, 31]. The compliance of the two
groups on home-based therapy was numerically and
substantially different, with patients using pdC1-INH
concentrates (71 % compliance) being apparently more
compliant than those using icatibant (44 % compliance).
The reason for this difference is unclear. A longer mean
time from diagnosis in patients on pdC1-INH (13 years)
vs. patients on icatibant (6 years) could account for this
difference, as a longer experience with the management
of attacks may be associated with a greater promptness
to treat them. In addition, the group treated with icati-
bant did not include any children because icatibant is
not approved for treatment in patients aged <18 years in
Italy, which may also account for a decreased tendency
to treat any attack. Our data also suggest that the lower
the number of attacks per month, the less the tendency
to treat the attacks. This, as well, may explain why pa-
tients on home-based therapy with icatibant (approxi-
mately 3 attacks per month) tend to have lower
compliance than patients on home-based C1-INH treat-
ment (more than 4 attacks per month).
In recent years, increasing effort has been devoted to
the study of patient-reported outcomes in HAE [32], in-
cluding the quality of life [24, 33]. Clinical outcomes
such as the severity and the frequency of attacks are
often insufficient to describe the full impact of HAE on
patients’ lives. The considerable burden of the disease
and its negative effect on patient quality of life is well
documented [24, 34–38]. A number of studies have also
investigated the impact of the switch to self-
administered therapy on the quality of life. One of these
studies assessed the quality of life using the Dermatology
Life Quality Index (DLQI) and the 36-Item Short Form
(SF-36) Health Survey questionnaires (neither of which
is validated for HAE) in seven patients switching to
home therapy [38]. The DLQI score improved in a sta-
tistically and clinically significant way, and the SF-36
showed substantial improvements in all items (physical
functioning, social functioning, physical role functioning,
emotional role functioning, mental health, vitality, bodily
pain, general health). A later study by the same authors
investigated the changes in the burden of illness before
and after the switch to home therapy using a question-
naire that addressed various aspects of the HAE burden,
namely the psychological impact, the impact on physical
activities, the worry about suffocation, the concern about
heredity, and the fear of treatment side effects [7]. The
switch was associated with a substantial and statistically
significant improvement in all five points considered. Al-
though the overall picture emerging from these studies
is that the switch to home therapy is associated with an
improvement in quality of life, there is a need for trials
assessing this outcome with tools specific for HAE. The
present study used a validated disease-specific question-
naire for use in patients with HAE [24]. Our findings
show, in contrast with most of the available evidence, a
trend towards lower quality of life in patients on home-
based treatment compared with those treated in the hos-
pital. A possible explanation is that our patients on
home therapy had a significantly higher frequency of at-
tacks and, likely, a more severe condition impacting
negatively on their quality of life. The comparison of
outcomes in patients stratified according to the disease
severity index, showed indeed a significant correlation
between severe disease (index ≥ 7) and reduced quality
of life. No difference in quality of life, and a worsening
in some domains, has also been reported by a recent
study [39]. This study, which used the SF-36 question-
naire (version 2), found a similar quality of life of self-
injecting and non-self-injecting patients, with the excep-
tion of the domain “general health”, which was signifi-
cantly worse in patients on self-therapy [39]. According
to the authors, this finding could be explained by the
fact that home-based therapy, despite a number of bene-
fits, may constantly remind patients of their chronic
condition. An association between high attack frequency
and low quality of life was reported also in a study using
the patient-completed EuroQol 5 Dimensions 5 Levels
(EQ5D-5L) questionnaire that evaluates health based on
five dimensions, including mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression [37].
Patients completed the questionnaire both for their
current health state and the state during their last HAE
attack. Patients with an attack frequency > 30 attacks per
Table 2 Therapy preference, compliance, and quality of life in patients stratified according to disease severity













DSS≥ 7 22 (70.9 %) 9 (29.1 %) 16 (51.6 %) 15 (48.4 %) 19 (67.8 %) 9 (32.2 %)
DSS < 7 15 (60.0 %) 10 (40.0 %) 11 (44.0 %) 14 (56.0 %) 10 (83.3 %) 2 (16.7 %)
Abbreviation definitions: DSS disease severity score, pct percentile
a Quality of life was assessed only in patients aged ≥ 18 years (n = 40)
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year were found to have a significantly lower perceived
current health state compared to those with less fre-
quent attacks.
The significantly higher frequency of attacks in our pa-
tients on home therapy compared with those treated in
the hospital suggests that this disease characteristic may
be predictive of a preference for home-based treatment.
Of note, the stratification of patients according to dis-
ease severity score (<7 or ≥ 7) did not reveal any signifi-
cant correlation with the use of home- or hospital-based
therapy suggesting that disease severity does not influ-
ence the choice of the treatment strategy. Furthermore,
no significant correlation was found between treatment
choice and other patient characteristics, including sex,
age, age at disease onset, and the level of education and
age. With regard to age, we expected that young age
would correlate with increased willingness to learn and
use self-therapy. We also expected that a longer time
since diagnosis would correlate with reduced willingness
to switch from hospital-based therapy to home-based
therapy, but this expectation was not confirmed by our
findings either. Notably, a recent update of the Icatibant
Outcome Survey (IOS) comparing icatibant self-
administration vs. administration by health care profes-
sionals failed to demonstrate that factors including sex,
use of long-term therapy, and attack location are pre-
dictive of the preference for self-administration [13].
The time from symptom onset and to therapy admin-
istration was not significantly different between home-
based and hospital-based treatment, though there was a
trend towards a more rapid administration in patients
treated at home (1.8 h for patients in treatment with
pdC1-INH at home vs. 3.1 h for patients treated with
pdC1-INH in hospital). Most data from the literature
show statistically significant improvements in time to
treatment after the switch from hospital to home ther-
apy [11, 13, 15, 38]. The reason why this variable did not
improve significantly in our patients is currently unclear.
The time from therapy administration to attack reso-
lution was not significantly different either between
the two treatment strategies; it was slightly longer
(>10 h for both home and hospital therapy) than
most values reported in the literature [9, 11, 40]. The
abovementioned update of the IOS comparing icati-
bant self-administration vs. administration by health
care professionals did not find either any significant
difference between the two treatment strategies with
regard to attack duration and time to resolution [13].
According to the authors this may be explained by an
improvement (shortening) in times to treatment also
in patients treated by healthcare professionals, a pos-
sible consequence of the increased compliance with
current guidelines that recommend to treat an attack
as early as possible.
The fact that variables including the number of attacks
and treated attacks, the time from symptom onset to
treatment administration, and the time from treatment
administration to symptom resolution were mostly based
on patient recollection and entry in their diaries may
have introduced some bias in the present study. The lack
of a severity assessment for each attack over the
6 months of observation, as well as the lack of informa-
tion about the body site affected, is another potential
limitation, as these variables, along with frequency, may
also influence the decision between hospital- and home-
based treatment. At the time of our observation there
were no generally accepted patient-reported outcome
tools such as, for example, the questionnaire for the as-
sessment of HAE recently developed by Bonner et al.
within the IOS [32]. We assessed instead the general se-
verity of disease based on patient medical records and
recollection using the severity scoring system developed
by Bygum et al., which takes into account objective vari-
ables like age of disease onset, body areas affected, and
need for long-term prophylaxis [23]. The observational
design and the small size of the analyzed population are
other limitations of our study. The latter limitation is
hard to avoid, as C1-INH-HAE is a rare disease and the
recruitment of sufficient patient numbers is extremely
difficult. Despite these limitations, the present study de-
scribes real-life C1-INH-HAE patients using different
strategies for the treatment of acute attacks and may
provide useful information with regard to patient sub-
groups most likely to benefit from self-administration.
Conclusion
Frequency of attack appears as an important factor in the
choice between home-based therapy and hospital-based
therapy. The use of home-based therapy with both pdC1-
INH and icatibant was found to correlate with high attack
frequency. Compared with hospital-based therapy, home-
based therapy with both medications was associated with
significantly better adherence to treatment, as measured
by the proportion of treated attacks, while no difference
was seen in patient quality of life. Treatment at home
should be offered to all patients with C1-INH-HAE and
especially to those with a high frequency of attacks.
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